...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medecine et maladies infectieuses >Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009
【24h】

Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009

机译：脂质体两性霉素B作为欧洲内脏利什曼病的治疗药物，2009年

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Visceral leishmaniasis (VL) causes an estimated 500,000 new cases of disease and more than 50,000 deaths a year. For more than 60 years, pentavalent antimonies were considered the standard therapy for VL. The emergence of Leishmania strains resistant to antimonials led to the evaluation of other treatments including amphotericin B and its lipidic derivatives. Clinical trials with liposomal amphotericin B demonstrated that total doses of 10 to 20mg/kg, administered according to various regimens, had a 90-98% efficacy in non-immunocompromised patients. Compared to antimonials, liposomal amphotericin B provides favorable efficacy/tolerance and cost efficacy ratios. The WHO recently produced consensus recommendations for the use of liposomal amphotericin B in VL. In Europe, liposomal amphotericin B has progressively become the reference treatment of VL in clinical practice, and it is recommended as the first line therapy.
机译：内脏利什曼病（VL）估计每年导致500,000例新疾病病例和50,000多例死亡。 60多年来，五价锑被认为是VL的标准疗法。对抗生素具有抗性的利什曼原虫菌株的出现导致对包括两性霉素B及其脂质衍生物在内的其他治疗方法的评估。脂质体两性霉素B的临床试验表明，根据各种方案给予的总剂量为10至20mg / kg，对非免疫功能低下的患者有90-98％的疗效。与抗生素相比，脂质体两性霉素B具有良好的药效/耐受性和成本效益比。世卫组织最近就在VL中使用脂质体两性霉素B达成了共识性建议。在欧洲，脂质体两性霉素B在临床实践中已逐渐成为VL的参考治疗方法，并被推荐作为一线治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号